As of Wednesday, February 25, MannKind Corporation’s MNKD share price has dipped by 13.18%, which has investors questioning ...
MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD’s 2026 business outlook highlights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results